Ημερομηνία - 08/03/2019 - 09/03/2019
We are proud to announce the first edition of the European NASH Workshop 2019. The workshop is scheduled for March 8-9 2019 and will take place in Barcelona, Spain.
Non-alcoholic fatty liver disease (NAFLD) is an emerging liver disease affecting 25 % of the population worldwide. In 10% of patients, NAFLD progresses into NASH, a fibrogenic phenotype that can potentially result in cirrhosis, liver failure and the formation of hepatocellular carcinoma.
Although NAFLD is globally the most prevalent chronic liver disease and the second leading indication for liver transplant evaluation in the US, knowledge concerning the molecular mechanisms favoring the development and progression of the disease are not fully understood. Current understanding supports the hypothesis that environmental and genetic factors equally influence disease progression.
Considering the far-reaching societal and economic burden caused by NAFLD, it is of utmost importance to identify and subsequently implement guidelines to stage, diagnose and treat the disease efficiently.
In particular, there is an unmet need for approved drugs that allow the pharmacological treatment of (pre-)cirrhotic NASH. By using surrogate endpoints, the drug approval process for NASH is accelerated and approved agents are expected to enter the market in the near future.
This workshop aims to train clincians on current and future treatment options. We specifically aim to provide practical guidance to secondary stakeholders, such as endocrinologists, diabetologists, cardiologists and general practitioners, on how to manage NAFLD/NASH.